| Related Articles |
Infections by multidrug-resistant Gram-negative Bacteria: what's new in our arsenal and what's in the pipeline?
Int J Antimicrob Agents. 2018 Oct 27;:
Authors: Koulenti D, Song A, Ellingboe A, Abdul-Aziz MH, Harris P, Gavey E, Lipman J
Abstract
The spread of multidrug resistant bacteria is an ever-growing concern especially among Gram-negative ones due to their intrinsic resistance as well as their ability to acquire and spread new resistance mechanisms rapidly. The challenge to treat infections by these organisms leaves medical practitioners helpless to their treatment and increases patient mortality as well as cost of care globally. This vulnerability, along with strategies to tackle antimicrobial resistance development, prompts the development of new antibiotic agents as well as exploration of alternative treatment options. This article summarises the new antibiotics that have recently been approved for Gram-negative bacterial infections, looks down the pipeline at promising agents currently in phase I, II, or III clinical trials, and introduces new alternative avenues that show potential in combating multidrug-resistant Gram-negative bacteria.
PMID: 30394301 [PubMed - as supplied by publisher]